Latest From Immutep Ltd.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Emerging Company Profile: Prima BioMed, a biotech developing immuno-oncology medicines, has been patiently waiting in the wings. Now, with three of its LAG-3 drug candidates partnered with pharma players, the company is ready to take center stage.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Prima BioMed Ltd.
- Parent & Subsidiaries
- Immutep Ltd.
- Senior Management
Marc Voigt, CEO
Frédéric Triebel, MD, PhD, CSO & CMO
- Contact Info
Phone: (61) 2 8315 7003
Level 12, 95 Pitt St.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.